CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 130 enrolled
Drug / intervention
Magnesium sulphate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06675500
NCT06675500Phase 3Completed
CompareCT.gov

Evaluation of the Role of Magnesium in Prevention of AF Post Cardiac Surgery

Ain Shams University·interventional·Posted Nov 5, 2024·Updated Aug 17, 2025

In Brief

A Phase 3 clinical trial evaluating Magnesium sulphate and Placebo for Atrial Fibrillation (AF) and 2 related conditions. Completed, enrolled 130 participants across 1 site.

Detailed Summary

Atrial fibrillation (AF) is a common complication after cardiac surgery. Most studies suggest that the frequency ranges between 25-40%. Some studies have shown that serum hypomagnesaemia is common after coronary artery bypass grafts (CABG) and other types of cardiac surgery and is associated with postoperative morbidity such as atrial tachyarrhythmia. The aim of the present study is to investigate the anti-arrhythmic effect of Magnesium Sulfate in prevention of atrial fibrillation post cardiac surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation (AF), Magnesium Sulfate, Post Cardiac Surgery Patients
CountriesEgypt
Collaborators--

Timeline

Phase 3CompletedFinished
20252026
First PostedNov 5, 2024
Enrollment StartNov 1, 2024
Primary CompletionApr 15, 2025
Study CompletionApr 30, 2025
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 1.7 years ago

Interventions

Magnesium sulphatedrug

Intravenous Magnesium sulphate followed by oral tablets of Magnesium sulphate

Placebodrug

Intravenous infusion of Normal saline 0.9 followed by starch oral tablets